To explore the metabolic and hepatic implications of Prader-Willi syndrome (PWS) and investigate novel methodologies for studying liver dysfunction associated with the condition.
Approach:
Genetic Mechanisms: The article discusses the genetic basis of PWS, highlighting paternal deletions, maternal uniparental disomy, and imprinting defects as primary causes.
Metabolic Profiling: Systemic lipidomic and metabolomic profiling is used to identify distinct metabolic signatures in PWS, particularly alterations in circulating phospholipids.
Model Development: Induced pluripotent stem cells (iPSCs) and hepatocyte-like cells (HLCs) are utilized as models to study the metabolic dysfunctions and liver involvement in PWS.
Key Findings:
PWS is characterized by obesity with a comparatively lower risk of insulin resistance and hepatic complications than typical obesity.
Distinct metabolic signatures in PWS include qualitative alterations in circulating phospholipids that may influence hepatic lipid export.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is reported to be less prevalent in PWS.
Interpretation:
Limitations:
The genotype-phenotype correlation in PWS remains unclear.
Variability in clinical manifestations complicates the understanding of PWS.
Conclusion:
The use of iPSC-derived models provides valuable insights into the mechanisms underlying liver dysfunction in PWS, aiding in therapeutic development.
